The development of new calcium channel blockers is still relevant for the understanding of
their physiological role and pharmacological and therapeutic purposes. For this task, natural …

Marrubenol inhibits contraction of rat arteries by blocking L-type calcium (Ca2+) channels in
smooth muscle cells, but its interaction with binding sites for calcium antagonists had never …

1, 12b-Cis-1-p-nitrobenzoyloxyindoloquinolizidine as well as 14 beta-p-
nitrobenzoyloxyyohimbine possessed potent calcium channel blocking activities in the …

Dihydropyridine derivative calcium‐channel blockers are widely used in the therapy of
hypertension, angina pectoris and other cardiovascular diseases. Because the prototype of …

The purpose of the present study was to investigate the effect of ligustilide on vasodilatation
in rat mesenteric artery and the mechanisms responsible for it. Isometric tension of rat …

Hypertension is a leading cause of death and disability globally, and its prevalence
continues to accelerate. The cardiovascular effects of the flavonoid tiliroside have never …

1. This experiment was designed to pharmacologically characterize a novel calcium channel
blocker, AE0047. 2. 2. After 1-hr treatment with each drug (10− 6 M), K+-induced contraction …

The present study was designed to investigate the relaxant effect of isopropyl 3-(3, 4-
dihydroxyphenyl)-2-hydroxypropanoate (IDHP), a new metabolite from Salvia miltiorrhiza …

Calcium channel antagonists have a well-established role in the management of
cardiovascular diseases. L-type calcium channels in vascular cells are a key therapeutic …

There is evidence to suggest that niflumic acid is capable of selectively inhibiting Ca2+-
dependent Cl− channels. Furthermore, it has been demonstrated that niflumic acid is …